Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
) x! y; x# h+ S4 K: tNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
4 k( n# v9 L9 d9 s+ Author Affiliations
" j5 f q! T! {' m# ^
' x1 q5 ] t) O# W* p+ \3 |: G1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan ) ^8 J6 D6 ]0 X( R- p
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 5 i1 z6 Q, B/ \- n% |+ x8 g+ Q
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
7 c- N7 D# H0 d8 G# \9 ^' E; e4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan . \ C/ d8 M7 O0 _2 q7 y
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan ) p( V9 T1 ?7 R0 O H+ k6 d
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
; F; \& \6 I% U/ e: Z4 W* A4 \- M7Kinki University School of Medicine, Osaka 589-8511, Japan : ]8 q2 t* M# t2 F5 p0 e" K! h1 b
8Izumi Municipal Hospital, Osaka 594-0071, Japan
3 a/ Z3 j& K: r7 j- A( D7 n9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan g" A( [; K2 P. }+ F; Q
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp 6 f- L7 c% C% K
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. 7 x6 G0 x9 Y f8 {
4 S: p9 S* P5 v) N' a+ S |